

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/28563 A1

- (51) International Patent Classification⁷: **A61K 31/58**, 9/51, 47/38
- (74) Agents: **ISHIDA, Takashi et al.**; A. Aoki, Ishida & Associates, Toranomon 37 Mori Bldg., 5-1, Toranomon 3-chome, Minato-ku, Tokyo 105-8423 (JP).
- (21) International Application Number: **PCT/JP00/07351**
- (22) International Filing Date: 20 October 2000 (20.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
11/298186 20 October 1999 (20.10.1999) JP
- (71) Applicant (for all designated States except US): **TEIJIN LIMITED** [JP/JP]; 6-7, Minamihommachi 1-chome, Chuo-ku, Osaka-shi, Osaka 541-0054 (JP).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **NAGANO, Atsuhiko** [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). **NISHIBE, Yoshihisa** [JP/JP]; Teijin Limited, Iwakuni Research Center, 2-1, Hinode-cho, Iwakuni-shi, Yamaguchi 740-0014 (JP). **TAKANASHI, Kazuya** [JP/JP]; Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP).
- Published:**
- With international search report.
 - Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/28563 A1

(54) Title: **CICLESONIDE-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION**

(57) Abstract: The present invention provides an aqueous pharmaceutical composition containing ciclesonide and hydroxypropyl-methylcellulose, wherein the ciclesonide is dispersed in an aqueous medium in the form of solid particles. The composition is able to avoid variations in the concentrations of ciclesonide during production as well as avoid decreases in the recovery rate of ciclesonide.

DESCRIPTION

CICLESONIDE-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION

Field of Invention

5 The present invention relates to a ciclesonide-containing aqueous pharmaceutical composition for use in drug therapy that contains ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in the form of solid particles. More particularly, the present invention relates to a ciclesonide-containing aqueous pharmaceutical composition having excellent ciclesonide dispersivity during production as compared with conventional aqueous pharmaceutical compositions.

15 Background Art

 Ciclesonide aqueous pharmaceutical compositions containing ciclesonide dispersed in an aqueous medium in a form of solid particles are expected to represent a useful drug form for reasons that include 1) it is not necessary to completely dissolve ciclesonide, 2) it can be directly administered to an affected site by spraying and so forth for treatment of local diseases such as those of the nasal mucosa, eyes and epidermis, and 3) they are easier to swallow than tablets or granule and so forth.

25 When present in an aqueous medium, ciclesonide is resistant to wetting and easily aggregates. The addition of wetting agent such as Polysorbate 80 and powerful stirring and so forth during production have been used in the prior art for the purpose of dispersing drug having such properties in an aqueous medium in a stable state.

30 Improvement of drug dispersivity of aqueous pharmaceutical compositions containing a drug dispersed in an aqueous medium in form of solid particles by addition of cellulose-based polymer is disclosed in Morishima et al. patent specification of W099-37286. However, this patent relates to the redispersion of a

drug that has settled during storage, and is fundamentally different from the present invention which relates to overcoming drawbacks of the migration of ciclesonide towards bubbles formed by powerful stirring during the production, and the adsorption of ciclesonide to the walls of the production apparatus. Moreover, the concentration of the cellulose-based polymer in the patent specification of Morishima et al. is 0.0001 to 0.003%, and methylcellulose can be used in place of hydroxypropylmethylcellulose for the cellulose-based polymer, while the addition of a nonionic surfactant is also required. It is not easy to deduce the present invention from this patent in which the optimum value of the hydroxypropylmethylcellulose concentration is from 0.01% w/w to 0.5% w/w, and does not require a surfactant.

Disclosure of the Invention

During the course of production of ciclesonide aqueous pharmaceutical compositions, high shearing force is required to disperse ciclesonide and it is necessary to powerfully stir ciclesonide-containing aqueous pharmaceutical composition. Ciclesonide migrates to the bubbles formed at this time. Since this results in an increased concentration of ciclesonide in the upper portion of the ciclesonide aqueous pharmaceutical composition being higher than that in the lower portion, variation occurs in the ciclesonide concentration of ciclesonide aqueous pharmaceutical compositions produced. Moreover, the recovery rate decreases due to adsorption of ciclesonide to the walls and so forth of the production apparatus.

These variations in ciclesonide concentration and adsorption of ciclesonide to the production apparatus were hardly improved at all by the addition of wetting agents such as Polysorbate 80 that have been used in the prior art. Conversely, the amount of formed bubbles increases resulting in promotion of further variation in ciclesonide concentration.

Therefore, there is a considerable need for the development of a ciclesonide aqueous pharmaceutical composition that is able to avoid variations in ciclesonide concentrations during production as well as the decrease in ciclesonide recovery rate.

Namely, the object of the present invention is to provide a ciclesonide aqueous pharmaceutical composition that avoids variations in ciclesonide concentration during production as well as decreases in the ciclesonide recovery rate.

As a result of earnest studies to solve the above problems, the inventors of the present invention found that a ciclesonide aqueous pharmaceutical composition can be provided that avoids variations in ciclesonide concentrations during production as well as decreases in the ciclesonide recovery rate, by using a ciclesonide aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, thereby leading to completion of the present invention.

Namely, the present invention relates to an aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in form of solid particles.

Embodiment for Carrying Out the Invention

It is essential that composition of the present invention contain ciclesonide, while water-soluble, water-low soluble or water-insoluble drugs other than ciclesonide can be added. Specific examples of these include vasoconstrictors, bronchodilators, anti-allergic agents and expectorants.

Although the ciclesonide particles that can be used in the present invention may be of any size, they are preferably within the range of 10 nm to 100 μ m, and particularly preferably within the range of 10 nm to 10 μ m.

Although any substances may be used for the water-insoluble or water-low soluble substance that can be used in the present invention, a preferable example is a cellulose, and a particularly preferable example is crystalline cellulose.

In the present invention, the concentration of water-insoluble substance and/or water-low soluble substance present in form of solid particles in an aqueous medium is preferably 0.3% w/w and above, and particularly preferably 1% w/w to 10% w/w, relative to the total amount of the composition.

In addition, an aqueous polymer substance can also be added in the present pharmaceutical composition. Specific examples of such include propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum arabic, carrageenan, methylcellulose, carboxymethylcellulose sodium, xanthan gum and hydroxypropylcellulose, while particularly preferable examples include carboxymethylcellulose sodium, polyethylene glycol and hydroxypropylcellulose. In addition, crystalline cellulose carmellose sodium, is an example of a combination of these water-soluble substances and water-insoluble substances that can be used in the present invention, and it consists of a mixture of carboxymethylcellulose sodium and crystalline cellulose. Furthermore, in the case of adding these water-soluble polymer substances, the concentration of said substance is preferably 1% w/w to 30% w/w relative to the water-insoluble substance and/or water-low soluble substance.

The ciclesonide-containing aqueous pharmaceutical composition of the present invention is also required to contain hydroxypropylmethylcellulose. Although this may be of any grade, a specific example is hydroxypropylmethylcellulose 2910.

Although said hydroxypropylmethylcellulose may be present at any concentration, its concentration is

preferably from 0.01% w/w to 30% w/w, particularly preferably from 0.01% w/w to 5% w/w, more particularly preferably from 0.01% w/w to 1% w/w, and most preferably from 0.01% w/w to 0.5% w/w, relative to the total amount of composition.

A wetting agent, although not essential in the present invention, can be added, specific examples of which include Polysorbate 80, glycerin monostearate, polyoxyl stearate, laurmacrogol, sorbitan oleate and sucrose fatty acid esters.

In the present invention, a substance for controlling osmotic pressure (osmotic pressure-controlling agent) can be added to control osmotic pressure, specific examples of which include salts such as sodium chloride and water-soluble sugars such as glucose, with glucose being a particularly preferable example.

An effective amount of ciclesonide used in the present invention can be determined according to the type and degree of the respective disease, as well as the age and body weight of the patient, and so forth.

The concentration of ciclesonide of the present invention is preferably from 0.01% w/w to 1% w/w, and particularly preferably from 0.05% w/w to 0.5% w/w, relative to the total amount of the composition.

Any method for dispersing a water-insoluble substance and/or water-low soluble substance in an aqueous medium may be used for the production of the ciclesonide-containing aqueous pharmaceutical composition in the present invention, a specific example of which is a method that uses a homomixer.

Known antiseptics, pH controlling agents, preservatives, buffers, colorants, smell corrigents and so forth may be added as necessary to the composition of the present invention to improve its physical properties, appearance or odor and so forth of the formulation. Examples of antiseptics include benzalkonium chloride,

examples of pH controlling agents include hydrochloric acid and sodium hydroxide, examples of preservatives include ascorbic acid, examples of buffers include phosphoric acid and its salt, examples of colorants include red dye no. 2, and examples of smell corrigents include menthol.

According to the present invention as described above, a ciclesonide aqueous pharmaceutical composition is provided that avoids variations in ciclesonide concentration during production as well as decreases in the recovery rate of ciclesonide more effectively than aqueous pharmaceutical compositions of the prior art. These effects also lead to improved quality as well as decreased production cost due to the higher recovery rate.

Thus, the present invention has extremely high significance in terms of both quality and economy for the production of ciclesonide aqueous pharmaceutical compositions.

Examples

The following provides an explanation of the present invention through its Examples.

Ciclesonide used in the present invention was manufactured by Byk Gulden Co., the crystalline cellulose carmellose sodium by Asahi Chemical Industry Co., Ltd. (Avicel™ RC-A591NF), hydroxypropylmethylcellulose 2910 by Shin-Etsu Chemical Co., Ltd. (TC-5RW™ or Metrose 60SH-4000™), Polysorbate 80 by Nippon Surfactant Co., Ltd., and the sorbitan trioleate by Nikko Chemical Co., Ltd. ROBOMICS™ manufactured by Tokushu Kika Kogyo Co., Ltd. was used for the homomixer.

Example 1

Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer. Homomixer processing was performed at 6000 rpm for 30

minutes.

Composition (1)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

5 Hydroxypropylmethylcellulose 2910 (TC-5RW™):

0.01% w/w

Composition (2)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

10 Hydroxypropylmethylcellulose 2910 (TC-5RW™):

0.1% w/w

Composition (3)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

15 Hydroxypropylmethylcellulose 2910 (TC-5RW™): 1% w/w

Composition (4)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

20 Hydroxypropylmethylcellulose 2910 (Metrose 60SH-
4000™): 0.01% w/w

Composition (5)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

25 Hydroxypropylmethylcellulose 2910 (Metrose 60SH-
4000™): 0.1% w/w

Immediately after processing compositions 1 to 5 with the homomixer, the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC. The value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.

35 Subsequently, the ciclesonide concentrations of the

ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.

Those values are shown in Table 1.

Comparative Example 1

Ciclesonide aqueous pharmaceutical compositions containing the components indicated below were prepared on a 300 ml scale by processing with a homomixer. Homomixer processing was performed at 6000 rpm for 30 minutes.

Composition (6)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

Polysorbate 80: 0.1% w/w

Composition (7)

Ciclesonide: 0.1% w/w

Crystalline cellulose carmellose sodium: 1.7% w/w

Sorbitan trioleate: 0.1% w/w

Immediately after processing compositions 6 and 7 with the homomixer, the ciclesonide aqueous pharmaceutical compositions were collected from the upper and lower portions of the emulsification tank, followed by quantification of the ciclesonide concentrations by HPLC. The value for the upper portion of the emulsification tank was calculated by taking the ciclesonide concentration in the lower portion of the emulsification tank to be 100%.

Subsequently, the ciclesonide concentrations of the ciclesonide aqueous pharmaceutical compositions recovered from the emulsification tank were quantified by HPLC, and the ciclesonide recovery rates were determined based on the theoretical value of the ciclesonide concentration as calculated from the charged amount.

Those values are shown in Table 1.

Table 1

	Preparation	Ciclesonide concentration immediately after processing		Recovery rate (%)
		(%)		
		Upper portion of emulsi-fication tank	Lower portion of emulsi-fication tank	
Embodiment 1	Composition 1	138.1	100.0	104.2
	Composition 2	100.3	100.0	100.7
	Composition 3	99.6	100.0	101.5
	Composition 4	147.9	100.0	98.4
	Composition 5	100.4	100.0	100.8
Comparative Example 1	Composition 6	131.1	100.0	78.2
	Composition 7	438.7	100.0	43.0

In the case of compositions 2, 3 and 5, which contained 0.1 to 1% w/w of hydroxypropylmethylcellulose 2910, the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were uniform, and the recovery rates were almost 100%. In addition, in the case of compositions 1 and 4, which contained 0.01% w/w of hydroxypropylmethylcellulose 2910, although the ciclesonide concentrations in the emulsification tank immediately after homomixer processing were somewhat non-uniform, the recovery rates were almost 100%. In contrast, in the case of composition 6, which contained 0.1% w/w of Polysorbate 80, the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 30% higher than in the lower portion. In addition, the recovery rate decreased by about 20%. In the case of composition 7, which contained 0.1% w/w of sorbitan trioleate, the ciclesonide concentration in the upper portion of the emulsification tank immediately after homomixer processing was more than 40% higher than in the lower portion, and the recovery rate decreased by more than half.

Based on these results, it was determined that the use of a composition containing hydroxypropylmethylcellulose made it possible to avoid variation in the concentration of ciclesonide during
5 production as well as avoid a decrease in the recovery rate of ciclesonide.

CLAIMS

1. An aqueous pharmaceutical composition containing ciclesonide and hydroxypropylmethylcellulose, wherein said ciclesonide is dispersed in an aqueous medium in form of solid particles.

2. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 30% w/w, relative to the total amount of the composition.

3. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 5% w/w, relative to the total amount of the composition.

4. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 1% w/w, relative to the total amount of the composition.

5. An aqueous pharmaceutical composition according to claim 1 wherein said hydroxypropylmethylcellulose concentration is from 0.01% w/w to 0.5% w/w, relative to the total amount of the composition.

6. An aqueous pharmaceutical composition according to any of claims 1 through 5 additionally containing one or more types of a water-insoluble substance and/or water-low soluble substance.

7. An aqueous pharmaceutical composition according to claim 6 wherein said water-insoluble substance and/or water-low soluble substance is a cellulose.

8. An aqueous pharmaceutical composition according to claim 7 wherein said cellulose is crystalline cellulose.

9. An aqueous pharmaceutical composition according to any of claims 1 through 8 additionally containing water-soluble polymer substance.

10. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is one or more types selected from the group consisting

of polyethylene glycol, propylene glycol alginate, pectin, low methoxyl pectin, gua gum, gum arabic, carrageenan, methylcellulose, carboxymethylcellulose sodium, xanthan gum and hydroxypropylcellulose.

5 11. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is carboxymethylcellulose sodium.

10 12. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is polyethylene glycol.

 13. An aqueous pharmaceutical composition according to claim 9 wherein said water-soluble polymer substance is hydroxypropylcellulose.

15 14. An aqueous pharmaceutical composition according to any of claims 1 through 13 wherein the combination of said water-insoluble substance and said water-soluble polymer substance is crystalline cellulose carmellose sodium.

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/JP 00/07351

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/58 A61K9/51 A61K47/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 25359 A (ASTRA) 27 May 1999 (1999-05-27) page 4, line 21 claims 1,3,7,9-12,28-31 page 8, line 4 - line 28 page 9, line 19 -page 10, line 3 examples 4,5	1-14
A	WO 99 47144 A (PHARMALINK) 23 September 1999 (1999-09-23) claims 1,2,6,14,16,18,22,23,25,28 page 5, line 12 -page 6, line 7	1-14
A	WO 98 52542 A (MINNESOTA MINING AND MANUFACTURING COMPANY) 26 November 1998 (1998-11-26) claims examples	1-14

	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

13 March 2001

Date of mailing of the international search report

23/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/JP 00/07351

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 199938 Derwent Publications Ltd., London, GB; Class A11, AN 1999-458604 XP002162689 & WO 99 37286 A (SANTEN PHARM CO LTD), 29 July 1999 (1999-07-29) cited in the application abstract</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati. Application No

PCT/JP 00/07351

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9925359	A	27-05-1999	AU 1266699 A	07-06-1999
			BR 9814118 A	03-10-2000
			CN 1285750 T	28-02-2001
			EP 1032396 A	06-09-2000
			NO 20002470 A	05-07-2000
			ZA 9810217 A	14-05-1999
<hr/>				
WO 9947144	A	23-09-1999	SE 514128 C	08-01-2001
			AU 2968699 A	11-10-1999
			BR 9908838 A	12-12-2000
			EP 1056461 A	06-12-2000
			SE 9800905 A	18-09-1999
<hr/>				
WO 9852542	A	26-11-1998	AU 726835 B	23-11-2000
			AU 7496298 A	11-12-1998
			BG 103902 A	31-05-2000
			BR 9809448 A	20-06-2000
			CN 1257421 T	21-06-2000
			EP 0983058 A	08-03-2000
			NO 995667 A	18-11-1999
			PL 336885 A	17-07-2000
			SK 157699 A	16-05-2000
			US 6120752 A	19-09-2000
<hr/>				
WO 9937286	A	29-07-1999	EP 1050299 A	08-11-2000
			JP 11279052 A	12-10-1999
			NO 20003650 A	05-09-2000
<hr/>				